Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Precision Medicine and Drug Development"
DOI: 10.1080/23808993.2021.1915126
Abstract: ABSTRACT Introduction: Cholangiocarcinomas (CCAs) are rare and heterogeneous malignancies associated with poor prognosis, with most of the patients presenting with advanced disease at diagnosis. The recent advent of molecular profiling has led to the identification… read more here.
Keywords: idh mutant; mutant cholangiocarcinoma; idh; ivosidenib idh ... See more keywords